AFE5BFD1-AA9F-470A-A44F-341126F8057D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.308804204993429
- age_years
- 43
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.709
- E2F_TARGETS+0.703
- G2M_CHECKPOINT+0.625
- MYC_TARGETS_V2+0.600
- DNA_REPAIR+0.588
- ANGIOGENESIS+0.529
- UNFOLDED_PROTEIN_RESPONSE+0.498
- MTORC1_SIGNALING+0.474
- OXIDATIVE_PHOSPHORYLATION+0.472
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.433
Top 10 suppressed
- KRAS_SIGNALING_DN-0.410
- BILE_ACID_METABOLISM-0.351
- MYOGENESIS-0.306
- APICAL_SURFACE-0.253
- ESTROGEN_RESPONSE_EARLY-0.163
- SPERMATOGENESIS-0.088
- UV_RESPONSE_DN-0.069
- APICAL_JUNCTION-0.044
- ESTROGEN_RESPONSE_LATE-0.008
- XENOBIOTIC_METABOLISM-0.007
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 541FDA8B-9FAE-4346-A6FD-C56735C87920 | — | — | 0.949 |
| 2 | 2E401C42-010F-4AFC-A362-B69426418626 | — | — | 0.944 |
| 3 | E24D233D-71BD-4EC2-A671-375917F24E5C | — | — | 0.941 |
| 4 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.941 |
| 5 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.939 |
| 6 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.935 |
| 7 | B27956E8-3374-4720-9F80-7CE6FE7C7690 | — | — | 0.934 |
| 8 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.932 |
| 9 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.930 |
| 10 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.709 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.703 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.625 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.588 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.529 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.498 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.474 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.472 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.433 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.355 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.326 | Idelalisib | — uncovered |
| APOPTOSIS | 0.325 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.325 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.301 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.257 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.252 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.244 | Inavolisib | — uncovered |